Lunai Bioworks Highlights AI Drug Discovery Platform on CNBC Amid Financial Recovery

Lunai Bioworks (NASDAQ: LNAI) was featured on CNBC's Business Minute on February 13, 2026, with the CEO discussing how the company is using its proprietary AI platform to scale therapeutic discovery for central nervous system disorders and advance biodefense countermeasures against emerging chemical and biological threats. The CNBC appearance underscores growing investor attention on scalable AI platforms transforming central nervous system therapeutics and national security-focused biodefense innovation.

During the national segment, the CEO discussed how Lunai integrates multimodal biological datasets, advanced machine learning, and in vivo validation systems to rapidly identify novel targets, optimize drug candidates, and compress development timelines across complex neurological disorders and emerging chemical and biological threat countermeasures. The platform is built to scale precision biology, reduce development risk, and advance high-impact therapeutic programs more efficiently.

Lunai is actively advancing discussions with leading pharmaceutical companies and government agencies around both their biotech and biodefense capabilities.

The company's latest Form 10-Q report showcased a notable improvement in financial performance. Net income reached $1.02 million, a substantial improvement from the previous year's loss of $51.46 million, primarily due to gains from the bankruptcy of a subsidiary. Basic and diluted income per share was $0.04, compared to a loss of $3.20 per share in the previous year, indicating improved profitability.

Total operating expenses decreased to $5.13 million, reflecting a significant decrease from the previous year's $57.88 million due to the absence of goodwill impairment charges. Net cash used in operating activities was $2.42 million, showing a reduction in cash outflow compared to the previous year's $4.58 million, attributed to better management of working capital.

Lunai Bioworks operates through two main segments: Renovaro Biosciences and BioSymetrics. Renovaro focuses on developing advanced cell and gene therapies for cancer and infectious diseases, while BioSymetrics specializes in biomedical AI for biomarker discovery and precision medicine. The company operates primarily in the United States and Canada, with BioSymetrics based in Canada.

Renovaro Biosciences is working on several innovative therapeutic platforms, including RENB-DC11 for solid tumors and RENB-DC20 for triple-negative breast cancer. These platforms aim to induce long-term remission in some of the deadliest cancers.

The company plans to focus on the development, validation, and commercialization of its AI-driven diagnostics and therapeutic platforms. Management is also seeking additional funding to support these initiatives and address the company's working capital needs. The bankruptcy of GediCube B.V., a subsidiary, led to its deconsolidation, impacting the company's operational structure.